This study aims to establish an autoimmune encephalitis cohort and observe the prognosis of patients with different subtypes and subgroups (e.g. epilepsy subgroup and teratoma subgroup ). Clinical characteristics, biological samples, and imaging data will be collected to discover blood and imaging biomarkers for providing support for the treatment, early warning, and outcome prediction.
Study Type
OBSERVATIONAL
Enrollment
200
At the time of enrollment, baseline characteristics will be collected, and each subject will be followed up for 2 years through face-to-face, telephone, or online visits. During the follow-up period, the clinical prognosis will be recorded.
Xuanwu Hospital, Capital Medical University
Beijing, China
Change in modified Rankin score (mRS) from baseline
Change in modified Rankin score (mRS) from baseline at month 1, month 3, month 6(mRS : Minimum Score 0, Maximum score 6, higher scores mean a worse outcome).
Time frame: 3months, 6 months, 12months, 24months
Proportion of Subjects With Occurrence
Time frame: 12 months, 24 months
Change of Clinical Assessment Scale in Autoimmune Encephalitis (CASE) Score from Baseline
The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score is designed specifically to assess the severity of autoimmune disease. It is a general scoring system ranging from 0 to 27 and can be used as an alternative tool to assess the severity of patients with AE more accurately. Higher scores mean a worse clinical status.
Time frame: 3months, 6 months, 12months, 24months
Changes of pathogenic antibody titers from baseline
Time frame: 3months, 6 months, 12months, 24months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.